Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Sort descending Project Status Date Submission Received Date Recommendation Issued
Paxlovid nirmatrelvir/ritonavir Mild-to-moderate COVID-19, treatment Active
Epidiolex cannabidiol Lennox-Gastaut Syndrome (LGS) Active
Epidiolex cannabidiol Dravet Syndrome (DS) Active
Libtayo cemiplimab Locally advanced or metastatic NSCLC (first line) Active
Isturisa osilodrostat Endogenous Cushing’s syndrome Suspended
Epidiolex cannabidiol Seizures associated with Tuberous Sclerosis Complex (TSC) Active
Remsima infliximab Crohn’s disease Active
Hemgenix etranacogene dezaparvovec Hemophilia B Active
Bimzelx bimekizumab Psoriatic arthritis Active
TBC risperidone Schizophrenia, adults Suspended